Category: Licensing/Collaboration Deal Region: Europe · Switzerland Company: Obseva Sa

ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million

By, Admin 1 min read
Share
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
ObsEva SA, a biopharmaceutical company developing novel therapies for women

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!